PFIZER INC — Director's Dealing 2024

Feb 27, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2024-02-23

Reporting Person: McDermott Michael (Executive Vice President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-02-23	Common Stock	M	12412.0000	$27.3400	Acquired	95408.0000	Direct
2024-02-23	Common Stock	F	859.0000	$27.7600	Disposed	94549.0000	Direct
2024-02-23	Common Stock	F	10031.0000	$27.3700	Disposed	84518.0000	Direct
2024-02-25	Common Stock	F	2992.0000	$27.7600	Disposed	81526.0000	Direct
2024-02-26	Common Stock	F	6063.0000	$27.1800	Disposed	75463.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-02-23	Stock Appreciation Rights	$27.3400	M	12412.0000	Disposed	2024-02-23	Common Stock (12412.0000)	Direct

Footnotes

F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).

F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.

F3: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).

F4: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.

F5: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).

F6: Price is the closing price of Pfizer common stock on February 23, 2024.

F7: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.